Evaluation of the impact of a prescribing guideline on the use of intraoperative dexmedetomidine at a tertiary academic medical center.

Autor: Alhammad AM; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States., Baghdady NA; Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States., Mullin RA; Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States., Greenwood BC; Clinical Pharmacy Service, University of Massachusetts, Commonwealth Medicine, Shrewsbury, MA 01545, United States.
Jazyk: angličtina
Zdroj: Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society [Saudi Pharm J] 2017 Jan; Vol. 25 (1), pp. 144-147. Date of Electronic Publication: 2016 Jan 14.
DOI: 10.1016/j.jsps.2016.01.002
Abstrakt: Objective: To evaluate usage patterns of dexmedetomidine in the operating room after implementation of a prescribing guideline. Methods: We conducted a retrospective analysis to evaluate the impact of a prescribing guideline on usage patterns of dexmedetomidine in the operating room at a tertiary, academic medical center during one-month period pre- (July 2010) and post-guideline (July 2011 and July 2012) implementation. Results: A total of 267 patients received intraoperative dexmedetomidine during the study period. Dexmedetomidine use in surgical procedures decreased post-guideline implementation [5.7% (pre) vs. 1.9% and 3.3% (post)]. The most common guideline-based indication for intraoperative dexmedetomidine was for anesthesia during bariatric surgery (41% and 38% in 2011 and 2012, respectively). We estimated a cost-avoidance of $308,856 over the two-year period after guideline implementation. Conclusion: Our results suggest that implementation of a prescribing guideline for the use of dexmedetomidine in the operating room is feasible and associated with improved utilization patterns.
Databáze: MEDLINE